ADD THIS DRUG TO MY LIST

Select the drug indication to add to your list

BEVESPI AEROSPHERE
Asthma/COPD
Compare To Related Drugs
View/Edit/Compare Drugs In My List

Only 4 drugs may be compared at once

Drug Name:

BEVESPI AEROSPHERE Rx

Generic Name and Formulations:
Glycopyrrolate 9mcg, formoterol fumarate 4.8mcg; per inhalation; metered-dose inhaler.

Company:
AstraZeneca Pharmaceuticals

Therapeutic Use:

Indications for BEVESPI AEROSPHERE:

Long-term maintenance treatment of airflow obstruction in COPD, including chronic bronchitis and/or emphysema.

Limitations Of use:

Not for the relief of acute bronchospasm or for the treatment of asthma.

Adult:

2 inhalations twice daily (in the AM + PM). Max 2 inhalations twice daily.

Children:

Not established.

Contraindications:

LABA use in asthma patients without use of long-term control medication.

Warnings/Precautions:

LABAs increase risk of asthma-related death. Not recommended for treating asthma. Do not initiate in patients during acutely deteriorating or potentially life-threatening COPD episodes. Not for treating acute symptoms. Prescribe a short-acting β2-agonist for acute symptoms; monitor for increased need. Do not exceed recommended dose. Discontinue immediately and treat if paradoxical bronchospasm or immediate hypersensitivity reactions occur; use alternative therapy. Cardiovascular disorders (eg, coronary insufficiency, cardiac arrhythmias, hypertension). Convulsive disorders. Thyrotoxicosis. Hyperresponsiveness to sympathomimetics. Diabetes. Ketoacidosis. Hypokalemia. Hyperglycemia. Narrow-angle glaucoma. Urinary retention. Prostatic hyperplasia. Bladder-neck obstruction. Hepatic disease; monitor. Severe renal impairment or ESRD requiring dialysis. Pregnancy (Cat.C). Labor & delivery. Nursing mothers: not recommended.

Interactions:

Not for use with other drugs containing LABAs. Caution with concomitant other adrenergic drugs; may potentiate sympathetic effects. Concomitant xanthine derivatives, steroids, or diuretics may potentiate hypokalemia. Caution with non-K+-sparing diuretics. Extreme caution with MAOIs, tricyclics, or others that prolong QTc interval. Antagonized by β-blockers; if needed, use cardioselective agents if no acceptable alternatives. Additive effects with concomitant other anticholinergic-containing drugs; avoid.

Pharmacological Class:

Anticholinergic + long-acting beta-2 agonist (LABA).

Adverse Reactions:

UTI, cough; paradoxical bronchospasm, hypersensitivity reactions, cardiovascular effects.

Generic Availability:

NO

How Supplied:

Inhalation aerosol—10.7g (120 inh)

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs